We promote the understanding of assessment and access processes for life science products to support the development and adoption of innovative treatments
We are a team of access specialists with decades of experience working in the pharmaceutical, biotech and medical technology sectors, within industry, in consulting and in the policy arena.
Our aim is to provide you with the knowledge and understanding to help you address your access challenges, and to continue to keep up to date in this rapidly changing field.
We help access professionals understand the complex processes and policies they need to follow, ensuring that innovative treatments reach patients with minimal delay.
Our international calendar of events connects you directly to the latest thinking and developments in access and helps you to grow your professional network.
The National Institute for Health and Disability Insurance INAMI/RIZIV has launched a mandatory electronic portal for all early and rapid medicine access applications.
The Cyprus Presidency of the EU will prioritise the finalisation of the Critical Medicines Act and the revision of the EU pharmaceutical legislation to address supply vulnerabilities and harmonise medicines access across the bloc.
The goal of this course is to demystify market access for anyone involved. You will be equipped with clear schematic overviews of the market access systems in Europe’s major markets as a resource for reference in your daily work.
This course offers a clear and practical introduction to statistical thinking tailored to the needs of Medical Affairs. You will learn the essential principles behind statistical analysis, develop the ability to critically assess the validity and relevance of study findings, and gain techniques to clearly communicate statistical results in a medical context.
Join us at this exceptional event, where senior managers, policymakers, commissioners, patients, frontline staff, and industry leaders unite in an inspiring and collaborative atmosphere
The Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) sets out how the prices for the majority of branded pharmaceuticals are controlled in the UK. The process applies across all four member nations and it allows manufacturers to freely set the list price of medicines, but with measures to contain NHS pharmaceutical spending.
The statutory scheme is the default UK mechanism for controlling NHS expenditure on branded health service medicines supplied by companies that do not participate in the voluntary scheme.
The ePACT2 system is a UK NHS Business Services Authority data and analytics platform used to analyse community prescribing and dispensing activity. It supports medicines optimisation, prescribing surveillance, budget management and contract monitoring, rather than prior approval or reimbursement authorisation.